If Black women are less likely than white women to be diagnosed with breast cancer, why are we more likely to die from it?
The gap has held for decades. Black women have about a five percent lower incidence rate and a 38 percent higher breast cancer mortality rate, according to the American Cancer Society’s 2024-2025 Breast Cancer Facts and Figures report. The disparity is even wider for younger women. Black women under 50 die from breast cancer at about twice the rate of white women the same age, and Black women have the lowest five-year survival rates at every stage of diagnosis.
Most of the conversation about why has centered on access, and rightly so. Later diagnoses, missed screenings, slower referrals, and uneven treatment all shape who lives and who doesn’t. In 2026, a genomic study added another piece to the picture, one that’s harder to see from the outside. It also points to something specific and reasonable you can ask your care team for. Empower your journey and survival with knowledge.
Researchers at Vanderbilt Health and the genomic testing company Agendia published a study in npj Breast Cancer that looked at more than 1,000 women with early-stage, hormone receptor-positive, HER2-negative breast cancer, one of the most common forms of the disease. Using two genomic tests, they sorted tumors by their molecular behavior rather than by appearance alone.
What they observed was that Black women were more than twice as likely to have aggressive basal-type tumors than white women, 11 percent compared to 4.8 percent. They were also more likely to carry high-risk luminal B tumors, which grow faster and come back more often than the less aggressive luminal A type. Women with these high-risk tumors were five to 10 times more likely to develop cancer that spreads to other parts of the body, regardless of race.
Once researchers accounted for tumor subtype, three-year survival was driven by the tumor’s biology, not by race. And the difference in subtypes held even after adjusting for socioeconomic factors. Just as telling, Black women with low-risk tumors did every bit as well as white women with low-risk tumors, with a 97.7 percent recurrence-free survival rate at 10 years. The tumor’s molecular type, not skin color, predicted the outcome.
RELATED: Breast Lumps: What’s Normal, What’s Not
When people hear “genetic testing” and breast cancer in the same sentence, they usually think of BRCA. That test looks at the DNA you were born with, most often from a blood or saliva sample, to see whether you carry an inherited mutation that raises your risk of developing cancer in the first place. It speaks to family history and future risk, and its results can shape decisions for you and your relatives.
Tumor genomic testing asks a different question. It reads the genes inside the cancer that’s already there. Tests like MammaPrint and BluePrint, the two used in the Vanderbilt study, along with Oncotype DX, measure how active certain genes are in the tumor to gauge its aggressiveness and likelihood of recurrence. MammaPrint analyzes 70 genes tied to recurrence, while BluePrint sorts tumors into luminal, HER2, or basal subtypes based on 80 genes.
That difference matters at the treatment table. A tumor genomic test can help your oncologist decide whether chemotherapy is worth it, how intensive your treatment should be, and whether a cancer that looks manageable under a microscope is actually behaving aggressively underneath. Two tumors can read as nearly identical on a standard pathology report and carry very different levels of danger. Genomic testing is one of the clearest ways to tell them apart.
RELATED: Certain Women May Need Mammograms Before Age 40 — An Expert Explains Why
If tumor biology helps explain part of the survival gap, then the testing that reveals it should reach everyone. That’s the case the study’s authors make directly. They argue that genomic testing for all patients could help guide treatment and narrow racial survival disparities.
Right now, that’s not what happens. Black women are less likely to receive genomic testing and less likely to receive recommended hormonal therapy, even in situations where the treatment path should look the same. Black women are also substantially less likely to get BRCA and other genetic testing, despite higher rates of early-onset and triple-negative disease. Additionally, the widely used Oncotype DX test may be less accurate for Black women, which makes broader, better-validated testing more important, not less.
None of this is a personal failing. These are gaps in what gets offered, explained, and paid for. But knowing the gap exists is what lets you close it in your own care.
You don’t need a science degree to advocate for yourself here. You need a few clear questions and the confidence to ask them.
Bring these to your oncologist:
If your doctor recommends against testing, that can be a completely sound call for your situation. The goal is to make sure the testing decision was made on purpose and explained to you, rather than skipped by default. You don’t have to demand a specific test to get there. A good oncologist will welcome the conversation.
If your care team brushes it off, that itself tells you something useful about whether you’re in the right hands.
It would be a mistake to read all this and conclude that Black women are simply destined for worse tumors. The research points somewhere more constructive, and so should your attention.
Most of the mortality gap still traces back to systemic factors: later-stage diagnoses, uneven access to timely screening, differences in treatment quality, insurance barriers, and the distance many women live from strong cancer care. Tumor biology is one thread in a much larger weave. Even the biological differences researchers are studying may partly reflect the long-term wear of stress and inequity on the body rather than any fixed racial destiny.
The good, actionable news is that the survival gap is not a permanent fact of nature. Where biology plays a role, testing can reveal it. Where access plays a role, advocacy and policy can change it.
And you don’t have to fix all of it to move your own odds. One informed question at your next appointment, one test requested, one second opinion when something feels off. Those are small, doable moves, and they beat waiting for a perfect moment that never comes. Your tumor has a story worth knowing, and you have every right to hear it. Your voice can save your life.
By subscribing, you consent to receive emails from BlackDoctor.com. You may unsubscribe at any time. Privacy Policy & Terms of Service.
Enter your name and email to receive the download link.
